Anti-Csf-1R Therapy With Combined Immuno- Chemotherapy Coordinate an Adaptive Immune Response To Eliminate Macrophage Enriched Triple Negative Breast Cancers

Authors

• Diego A Pedroza
• Xueying Yuan
• Fengshuo Liu
• Hilda L Chan
• Christina Zhang
• William Bowie
• Alex J Smith
• Sebastian J Calderon
• Nadia Lieu
• Weiguo Wu
• Paul Porter
• Poonam Sarkar
• Na Zhao
• Constanze V Oehler
• Ondrej Peller
• M Waleed Gaber
• Qian Zhu
• Charles M Perou
• Xiang H-F Zhang
• Jeffrey M Rosen

Language

English

Publication Date

5-6-2025

Journal

bioRxiv

DOI

10.1101/2025.04.30.651522

PMID

40568104

PMCID

PMC12191229

PubMedCentral® Posted Date

5-6-2025

PubMedCentral® Full Text Version

Pre-Print

Abstract

Patients diagnosed with metastatic triple negative breast cancer (mTNBC) have limited treatment options, are more prone to develop resistance and are associated with high mortality. A cold tumor immune microenvironment (TIME) characterized by low T cells and high tumor associated macrophages (TAMs) in mTNBC is associated with the failure of standard-of-care chemotherapy and immune checkpoint blockade (ICB) treatment. We demonstrate that the combination of immunomodulatory metronomic Cyclophosphamide (CTX) coupled with anti-CSF-1R antibody targeted therapy (SNDX-ms6352) and anti-PD-1 (ICB), was highly effective against aggressive metastatic syngeneic

Published Open-Access

yes

Recommended Citation

Pedroza, Diego A; Yuan, Xueying; Liu, Fengshuo; et al., "Anti-Csf-1R Therapy With Combined Immuno- Chemotherapy Coordinate an Adaptive Immune Response To Eliminate Macrophage Enriched Triple Negative Breast Cancers" (2025). Faculty, Staff and Students Publications. 8050.
https://digitalcommons.library.tmc.edu/baylor_docs/8050